End-To-End Advanced Therapy CDMO Services

Advanced therapy development demands more than manufacturing capacity. The technical, logistical, and regulatory complexity involved in moving a cell or gene therapy from discovery to commercialization requires a partner with depth across every stage of the process, not just isolated capability in one area.

This brochure details a comprehensive suite of advanced therapy CDMO services covering translational research, viral vector development and manufacturing, cell therapy, mRNA production, cold and ultra-cold supply chain management, and integrated program coordination. It outlines specific service pathways, facility capabilities, and development frameworks designed to address the distinct challenges of each modality, including the Rapid Development Framework for both cell and viral vector programs and co-located mRNA production through fill-finish.

With approximately 49% of FDA-approved cell and gene therapy products supported through these CDMO and CRO services, and more than 13 facilities across North America, Europe, and Asia, the scope of this offering spans the full customer journey. Explore the complete capabilities overview to understand what end-to-end support looks like in practice.